share_log

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $57

Benzinga ·  Nov 9, 2023 09:37

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $54 to $57.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment